Cancer immunotherapy company Arcus Biosciences up 14% in IPO – San Francisco Chronicle
San Francisco Chronicle |
Cancer immunotherapy company Arcus Biosciences up 14% in IPO
San Francisco Chronicle Arcus Biosciences Founder and CEO Terry Rosen, right, is applauded as he rings a ceremonial bell when his company's IPO begins trading on the floor of the New York Stock Exchange, Thursday, March 15, 2018. (AP Photo/Richard Drew). Arcus Biosciences … |
